Information Provided By:
Fly News Breaks for March 1, 2018
AMED
Mar 1, 2018 | 08:03 EDT
Oppenheimer analyst Michael Wiederhorn raised his price target for Amedisys to $68 from $63 saying that while Q4 results and guidance were received with mixed reviews, the company continues to improve growth and margins in home health, and hospice continues to hit on all cylinders. Furthermore, the analyst notes the reimbursement outlook is much-improved with multi-year visibility. Wiederhorn reiterates an Outperform rating on the shares and says he would continue to be a buyer of the stock on any weakness.
News For AMED From the Last 2 Days
There are no results for your query AMED
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.